Despite only modest activity as single agents [3, 4], monoclonal antibodies targeting EGFR such as cetuximab and pan-EGFR/ERBB inhibitors continue to attract significant clinical attention in HNSCC [2, 4–6]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.